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A B S T R A C T
Background
Venom immunotherapy (VIT) is commonly used for preventing further allergic reactions to insect stings in people who have had a
sting reaction. The efficacy and safety of this treatment has not previously been assessed by a high-quality systematic review.
Objectives
To assess the effects of immunotherapy using extracted insect venom for preventing further allergic reactions to insect stings in people
who have had an allergic reaction to a sting.
Search methods
We searched the following databases up to February 2012: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane
Library, MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1806), AMED (from 1985), LILACS (from 1982), the
Armed Forces Pest Management Board Literature Retrieval System, and OpenGrey. There were no language or publication status
restrictions to our searches. We searched trials databases, abstracts from recent European and North American allergy meetings, and
the references of identified review articles in order to identify further relevant trials.
Selection criteria
Randomised controlled trials of venom immunotherapy using standardised venom extract in insect sting allergy.
Data collection and analysis
Two authors independently undertook study selection, data extraction, and assessment of risk of bias. We identified adverse events
from included controlled trials and from a separate analysis of observational studies identified as part of a National Institute for Health
and Clinical Excellence Health Technology Assessment.
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Main results
We identified 6 randomised controlled trials and 1 quasi-randomised controlled trial for inclusion in the review; the total number of
participants was 392. The trials had some risk of bias because five of the trials did not blind outcome assessors to treatment allocation.
The interventions included ant, bee, and wasp immunotherapy in children or adults with previous systemic or large local reactions to
a sting, using sublingual (one trial) or subcutaneous (six trials) VIT. We found that VIT is effective for preventing systemic allergic
reaction to an insect sting, which was our primary outcome measure. This applies whether the sting occurs accidentally or is given
intentionally as part of a trial procedure.
In the trials, 3/113 (2.7%) participants treated with VIT had a subsequent systemic allergic reaction to a sting, compared with 37/
93 (39.8%) untreated participants (risk ratio [RR] 0.10, 95% confidence interval [CI] 0.03 to 0.28). The efficacy of VIT was similar
across studies; we were unable to identify a patient group or mode of treatment with different efficacy, although these analyses were
limited by small numbers. We were unable to confirm whether VIT prevents fatal reactions to insect stings, because of the rarity of this
outcome.
Venom immunotherapy was also effective for preventing large local reactions to a sting (5 studies; 112 follow-up stings; RR 0.41, 95%
CI 0.24 to 0.69) and for improving quality of life (mean difference [MD] in favour of VIT 1.21 points on a 7-point scale, 95% CI
0.75 to 1.67).
We found a significant risk of systemic adverse reaction to VIT treatment: 6 trials reported this outcome, in which 14 of 150 (9.3%)
participants treated with VIT and 1 of 135 (0.7%) participants treated with placebo or no treatment suffered a systemic reaction to
treatment (RR 8.16, 95% CI 1.53 to 43.46; 2 studies contributed to the effect estimate). Our analysis of 11 observational studies found
systemic adverse reactions occurred in 131/921 (14.2%) participants treated with bee venom VIT and 8/289 (2.8%) treated with wasp
venom VIT.
Authors’ conclusions
We found venom immunotherapy using extracted insect venom to be an effective therapy for preventing further allergic reactions to
insect stings, which can improve quality of life. The treatment carries a small but significant risk of systemic adverse reaction.
P L A I N L A N G U A G E S U M M A R Y
Immunotherapy for preventing allergic reactions to insect stings
At least 1 in 200 people have suffered a severe allergic reaction to a sting from a bee, wasp, or ant, and insect stings are the second
most common cause of fatal allergic reactions in some countries. Treatment with insect venom, usually given by a course of injections
(called venom immunotherapy), is thought to reduce the risk of allergic reactions to an insect sting. In this review, we evaluated the
effectiveness of venom immunotherapy for preventing allergic reactions to insect stings.
From analysis of 7 studies, which included 392 participants, we found that this treatment reduces the chance of having a serious allergic
reaction to an insect sting by 90%, a consistent finding between studies. Venom immunotherapy also significantly improves the quality
of life of people who have had a serious allergic reaction to an insect sting by reducing anxiety and possible limitation of activities caused
by fear of insects. However, almost 1 in 10 people treated with venom immunotherapy during the trials had an allergic reaction to their
treatment. We were unable to find out whether venom immunotherapy prevents fatal allergic reactions to insect stings, because these
are so rare. The decision whether to start venom immunotherapy depends on an accurate diagnosis, followed by careful assessment of
a person’s risk of having another allergic reaction to a sting, the degree to which the insect sting allergy affects their quality of life, and
the risk of an allergic reaction to their treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Venom immunotherapy compared with no venom immunotherapy for insect sting allergy
Patient or population: adults and children with a previous allergic react ion to an insect st ing
Setting: allergy referral units in USA (3 trials), Netherlands (2 trials), Italy, and Australia
Intervention: venom immunotherapy
Comparison: no venom immunotherapy




Quality of the evidence
(GRADE)
Comments





to an insect sting
Follow-up: between 6
weeks and 4 years







83 per 1000 8 per 1000
(2 to 23)
M edium- risk population
398 per 1000 40 per 1000
(12 to 111)
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treatment
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; VQLQ: Venom Quality of Life Quest ionnaire
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
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B A C K G R O U N D
Description of the condition
Insect sting allergy is a common cause of severe allergic reactions
(anaphylaxis) and may be fatal. Reported allergy to insect stings is
confined to insects from the order Hymenoptera, which includes
bees, wasps, and ants. The population-based prevalence of a his-
tory of Hymenoptera sting systemic reactions (SRs; that is, reac-
tions involving areas of the body beyond the site of the sting) is
approximately 0.3% to 7.5% depending on the diagnostic criteria
used (Bilo 2005). In children, and based on few studies, the preva-
lence rate of SRs is lower than in adults, ranging from 0.15% to
0.8% (Bilo 2009). The prevalence of SRs to sting exposure among
beekeepers is high and ranges from 14% to 32% (Muller 2005).
The relative prevalence of SRs to different species within the Hy-
menoptera order varies according to the prevalence of species that
deliver potentially allergenic venom in the local region. For ex-
ample, in South-Eastern Australia, the jack jumper ant (Myrmecia
pilosula) is a common cause of SRs. In the Americas, imported
fire ants (a species of the genus Solenopsis) are common, but in
both Europe and North America, SRs are most commonly caused
by wasps (especially species of the genus Vespula) or honey bees
(Apis mellifera) (Bilo 2005). In Europe, the term ’wasp’ is typically
used to include all members of the Vespidae family (e.g. ’European
wasp’, ’paper wasp’, ’hornets’, ’yellowjacket’); in North America,
species of Vespula and Dolichovespula genera are termed ’yellow-
jackets’, and species of the genus Polistes are termed ’wasp’. In this
review, we used the European terminology, with the exception of
the description of the interventions in the ’Characteristics of in-
cluded studies’ tables (Characteristics of included studies), where
we retained the authors’ original descriptions.
Although the incidence of insect sting mortality is low, ranging
from 0.03 to 0.48 fatalities per 1,000,000 inhabitants per year
(Antonicelli 2002; Bilo 2005), this may be an underestimate due
to miscoding of the cause of death. It is estimated that 40 to 100
fatal sting reactions occur each year in the USA (Pumphrey 2000).
Recent studies in the UK and Australia have demonstrated that
sting allergy comes second only to drug allergy as a cause of fatal
anaphylaxis, accounting for two to three times as many deaths as
food anaphylaxis (Clark 2007; Liew 2009). Men over 40 years of
age with concomitant cardiovascular disease and a previous history
of Hymenoptera sting allergy are at the highest risk of severe and
fatal anaphylactic sting reactions. Other factors that increase the
risk of a severe or fatal sting reaction include the use of certainmed-
ications (e.g. beta blockers), stings in the head or neck, bee stings,
a rare condition called mastocytosis (where there is an accumula-
tion of mast cells or mastocytes in various organs), and delayed or
lack of use of adrenaline to treat the reaction (Bilo 2005; Rueff
2009). Recently, high baseline serum tryptase concentrations and
angiotensin-converting enzyme (ACE) inhibitor medication were
found to be associated with increased risk of severe anaphylactic
reactions (Bonadonna 2009; Rueff 2009).
Hymenoptera sting allergy can manifest as large local reactions
(LLRs) or SRs, which are mostly immunoglobulin (IgE)-medi-
ated. A LLR is commonly defined as a swelling exceeding 10 cm in
diameter and lasting at least 24 hours. In SRs, the skin, gastroin-
testinal, respiratory, and cardiovascular systems may be involved.
In children, about 60% of SRs are mild and restricted to the skin,
whereas in adults, respiratory or cardiovascular symptoms occur
in about 70% of SRs (Brown 2004).
Allergic sting reactions are responsible for significant morbidity,
and they may have a detrimental effect on health-related quality
of life. They may also deter people from carrying on their normal
daily activities (Oude Elberink 2003).
Identifying the insect species to which the person has reacted is an
important step for effectivemanagement of Hymenoptera sting al-
lergy (Golden 2005). Diagnosis of Hymenoptera venom allergy is
based on a clear clinical history of allergic reaction toHymenoptera
sting and demonstration of a positive skin test, venom-specific al-
lergy antibodies (IgE) in serum, or both.
The current treatment for insect venom allergy includes advice to
minimise exposure to further stings, prescription of self-admin-
istered adrenaline, and venom immunotherapy (VIT) in selected
people. Although both pure insect venom and whole body extract
have been used for allergen immunotherapy of people with insect
sting allergy, this review only considered trials of VIT using in-
sect venom. Venom immunotherapy using whole body extract is
thought to be ineffective for preventing allergic reactions to bee or
wasp stings (Hunt 1978), but it is thought to be effective for pre-
venting allergic reactions to imported fire ant (Solenopsis invicta)
stings (Freeman 1992).
Description of the intervention
Venom immunotherapy is the only allergen-specific treatment
available to prevent future severe reactions in those who are allergic
to insect stings. Adults who experience an anaphylactic reaction
to an insect sting have a 40% to 60% risk of reacting to a further
sting (Bilo 2009). This risk may be reduced by VIT. Venom im-
munotherapy involves the administration of gradually increasing
doses of the insect sting venom to which the person is allergic,
in order to induce a state of tolerance to subsequent stings. The
standard form of VIT is subcutaneous injections given at intervals
of one to eight weeks for a period of three to five years. However,
some centres use accelerated injection protocols in the initial phase
(called rush or ultra-rush updosing), and the use of sublingual VIT
is also being investigated. Treatment plans of various durations
have been devised in an effort to maximise protection, minimise
side-effects, and optimise convenience for the affected person. In
North America, VIT is recommended for all adults who have ex-
perienced a SR following an insect sting (Moffit 2004), whereas in
many European centres, VIT is only recommended for the most
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severe reactions (Bonifazi 2005). Venom immunotherapy is usu-
ally given for three to five years, and it is thought to lead to a long-
term reduction in the risk of allergic reaction to an insect sting,
even after the treatment course has finished (Golden 2011).
How the intervention might work
Venom immunotherapy is thought to change the way in which
the body’s immune system responds to insect venom when it is in-
troduced into the body through a sting. It modulates both T- and
B-cell response to the allergen (Ewan 2001), with early produc-
tion of interleukin-10 (IL-10) and induction of T-cell “anergy”
(Akdis 2007). Venom immunotherapy is also associated with an
increase in venom-specific IgG4 and a gradual fall in specific IgE
(Wilson 1994). Although the majority of adverse effects of VIT
are very mild, there is a risk of systemic allergic reaction to the
treatment (Mosbech 2000). The success rate of VIT varies in dif-
ferent centres. Accidental (field) sting and sting challenge are the
most reliable means of evaluating the effectiveness of VIT since
there is a poor correlation between levels of allergen-specific serum
immunoglobulin and risk of reacting to a sting (Senti 2006). Sting
challenges are commonly used in clinical trials, but they may elicit
inconsistent responses, can carry a significant risk of severe allergic
reaction, and may induce further sensitisation (Bilo 2005).
Why it is important to do this review
Despite its common use for the prevention of anaphylactic reac-
tions to insect stings, there has been no high-quality systematic
evaluation of the effectiveness and safety of insect VIT. There is
some variation in the use of VIT in clinical practice, and a pre-
cise estimate of the overall treatment efficacy and safety would be
valuable to inform clinical decision-making and policy.
O B J E C T I V E S
To assess the effects of immunotherapy using extracted insect
venom for preventing further allergic reactions to insect stings in
people who have had an allergic reaction to a sting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing VIT
with placebo, no treatment, or back-up treatment, such as educa-
tion and provision of self-administered adrenaline, for prevention
of insect sting reactions.
Types of participants
We included all participants with previous systemic reactions (SR)
or large local reactions (LLR) to any insect sting, a positive skin
test, serum-specific IgE, or both, to insect venom in this review,




We included studies using standardised venom extract in any form
of immunotherapy (subcutaneous or sublingual). We included all
appropriate allergens at all doses and all durations of treatment.
We also planned to include studies that used a mix of different
extracts, e.g. bee and wasp together. We did not include studies
that used whole body extract.
Control
The control intervention took the form of a placebo, no treat-
ment, or back-up treatment for the prevention of fatal insect sting
anaphylaxis, such as education and provision of self-administered
adrenaline. In trials comparing more than one treatment arm to a
control group, we only included the treatment arm using standard
venom extract compared to a control group.
Types of outcome measures
Primary outcomes
1. Systemic reaction to a ’field’ insect sting or a sting challenge
during treatment. Where studies reported multiple time points
for this outcome measure, we used the closest time point to the
end of VIT. Where possible, we graded SRs as mild, moderate, or
severe using the scoring method of Brown (Brown 2004). Where
SRs were graded using the method of Mueller (Mueller 1966),
we classed grade 1 reactions as ’mild’, grades 2 and 3 as
’moderate’, and grade 4 as ’severe’.
2. Fatal SR due to a field or challenge insect sting over the
same period.
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Secondary outcomes
1. Large local reactions to a field sting or sting challenge
during treatment or during the 10 years following treatment.
2. Quality of life or anxiety score, assessed using a published
scale (Oude Elberink 2002).
3. Adverse events to immunotherapy (local reaction, systemic
reaction).
Search methods for identification of studies
We aimed to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases up to 21 February 2012:
• the Cochrane Skin Group Specialised Register using the
following terms: allerg* and (bite* or sting*) and immuno*;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library using the search strategy
in Appendix 1;
• MEDLINE (from 1946) using the strategy in Appendix 2;
• EMBASE (from 1974) using the strategy in Appendix 3;
• PsycINFO (from 1806) using the strategy in Appendix 4;
• AMED (Allied and Complementary Medicine, from 1985)
using the strategy in Appendix 5; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 6.
We also searched the Armed Forces PestManagement Board Liter-
ature Retrieval System (LRS) (http://lrs.afpmb.org/) on 21 Febru-
ary 2012, using the terms ’venom AND immunotherapy’ and ’al-
lergy AND [immunotherapy OR desensitization]’.
Trials registers
We searched for reports of trials in the following databases on 21
February 2012:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).




We searched the proceedings of the European Academy of Allergy
and Clinical Immunology (EAACI) from 2008 to 2010 and the
American Academy of Allergy, Asthma & Immunology (AAAAI)
from 2008 to 2011 for relevant studies.
Reference lists
We searched the reference lists of studies and review articles for
further references to relevant trials.
Grey literature
We searched for grey literature through the OpenGrey database
(previously called ’System for Information on Grey Literature in
Europe’) at http://opensigle.inist.fr/ using the term ’venom im-
munotherapy’ on 28th December 2010. This search was not run
again as no new material has been added to the database since
2005.
Correspondence
We contacted the authors of all included trials for additional data
and clarificationofmethodology.We contactedVITproductman-
ufacturers for information on published or unpublished studies
relevant to our review - HollisterStier, Stallergenes, ALK-Abello,
and Allergy Therapeutics.
Language
We imposed no language restrictions on our search. We included
studies published in languages other than English if they fulfilled
the inclusion criteria.
Adverse effects
In addition to looking for adverse effects of VIT in the included
studies, we included data from an adverse events analysis of ob-
servational studies, undertaken as part of a National Institute for
Health and Clinical Excellence Health Technology Assessment of
Pharmalgen VIT (Hockenhull 2012).
Data collection and analysis
Selection of studies
ME and RB independently reviewed the titles and abstracts of the
studies identified by the literature search. We assessed included
studies against the preset inclusion criteria.
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Data extraction and management
ME and RB independently extracted data from the included stud-
ies onto a specially-prepared data extraction form. RB and ME
contacted all trial authors to clarify any questions about method-
ology and to obtain any missing data. ME entered all quantitative
results into Review Manager 5 (RevMan), and RB checked this.
Assessment of risk of bias in included studies
We assessed and documented themethodological quality of the in-
cluded studies. Two authors (ME and RB) independently assessed
the risk of bias of each trial using The Cochrane Collaboration’s
’Risk of bias’ tool (Higgins 2009). We made judgments on the
risk of bias in six domains: sequence generation, allocation con-
cealment, blinding (of participants, personnel, and outcome asses-
sors), incomplete outcome data, selective outcome reporting, and
other sources of bias. We planned to incorporate this assessment
into the interpretation of results by performing sensitivity analy-
ses, excluding studies with the highest risk of bias. Each domain
is addressed in the ’Risk of bias’ table for each study, which is part
of the ’Characteristics of included studies’ table. These judgments
are categorised as ’low risk of bias’, ’high risk of bias’, or ’unclear
risk of bias’.
Measures of treatment effect
We calculated the risk ratio (RR) with 95% confidence intervals
(CI) for dichotomous (binary) data. We calculated the mean dif-
ference (MD) with 95%CIwhen continuous outcomes weremea-
sured on standard scales. We performed all analysis on the basis
of intention-to-treat. For analysis of risk of systemic reaction, we
used the number of participants stung during the follow-up pe-
riod as the denominator in each study. However, we performed a
secondary analysis using the number of participants randomised
and assessed for possible sting reaction during follow-up as the
denominator in each study.
Unit of analysis issues
For cross-over trials we planned to use the first treatment period as
a parallel-group study and ignore the crossing-over, since a cross-
over design might not be appropriate for immunotherapy studies.
We listed non-randomised controlled studies, but did not discuss
them further. When studies reported more than one active inter-
vention, we planned to analyse the active groups separately, but
divide the number of participants in the control group. Where
studies reported outcomes as non-parametric statistics, we planned
to include these in meta-analysis where possible by asking authors
for original datasets.
Dealing with missing data
If we noted significant dropout of participants, we planned to con-
duct an intention-to-treat analysis without imputing missing data.
We contacted all authors for details about study design, descriptive
statistics, or other information as necessary. We only analysed the
available data and planned to discuss the impact of the missing
data on our findings where large amounts of outcome data were
missing.
Assessment of heterogeneity
We assessed heterogeneity among trials using the I² statistic (I²
statistic > 30% was considered as significant heterogeneity, and
I² statistic > 80% was considered as substantial heterogeneity).
Where substantial heterogeneity existed between studies for the
primary outcome, we planned to explore the reasons for hetero-
geneity and not pool trial results. However, there was a low level
of heterogeneity between trials for the primary outcome.
Assessment of reporting biases
We planned to assess publication bias using a funnel plot for the
primary outcome measures if at least 10 trials were included in
these analyses; however, we had less than 10 included studies.
Data synthesis
WeusedReviewManager 5 to analyse data.Datawere analysed us-
ing the intention-to-treat principle, i.e. all participants were anal-
ysed in the treatment group to which they were randomised, inde-
pendent of their actual treatment. We combined all relevant data
extracted from included studies in a meta-analysis provided that
there was sufficient homogeneity (i.e. I² statistic≤ 80%) amongst
studies. Where substantial heterogeneity (I² statistic > 80%) was
found, we planned to explore this by prespecified sensitivity and
subgroup analysis. We used a random-effects meta-analysis as an
overall summary. Where meta-analyses were not applicable, we
used a narrative synthesis of outcomes from relevant studies.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses to explore potential sources of
heterogeneity, with appropriate tests of interaction. Prespecified
subgroups were as follows:
1. Type of immunotherapy: subcutaneous versus sublingual
VIT.
2. Age of participants: 18 years or over and under 18 years.
3. Duration of immunotherapy: up to 1 year, 1 to 3 years, and
over 3 years.
4. Type of insect sting allergy: bees, wasps, and ants.
5. Type of immunotherapy updosing regimen: rush/ultra rush
versus standard weekly or 2-weekly updosing.
9Venom immunotherapy for preventing allergic reactions to insect stings (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analysis
Where substantial heterogeneity was found in meta-analysis of
primary outcomes (I² statistic > 80%), we planned to explore
possible reasons for this in sensitivity analyses, including quality
of included studies. However, we did not undertake sensitivity
analyses because of the small number of trials contributing data
to the analyses and the low level of heterogeneity between trial
outcomes for most analyses.
R E S U L T S
Description of studies
Results of the search
The search identified 316 titles. We reviewed the full articles for
31 titles, and these yielded 10 separate publications relating to
6 RCTs (Brown 2003; Hunt 1978; Oude Elberink 2006; Oude
Elberink 2009; Severino 2008; Valentine 1990) and 1 quasi-ran-
domised controlled trial (Golden 2009), including 392 partici-
pants for inclusion in the review. A search of references from all
included studies and a review of all identified review articles did
not identify any new trial of VIT that could be included in the
systematic review. We contacted the authors of all the trials for
original data and clarification of methods; we received further de-
tails from the authors or their collaborators for all trials (Brown
2003; Golden 2009; Hunt 1978; Severino 2008; Oude Elberink
2006; Oude Elberink 2009; Valentine 1990).
For two RCTs, earlier publications described outcomes in a subset
of participants that were also included in a later report (Oude
Elberink 2006; Valentine 1990).
Included studies
Of the seven trials included in the review, one studied children
(Valentine 1990); one studied both adults and children (Hunt
1978); and five studied adults (Brown 2003; Golden 2009; Oude
Elberink 2006; Oude Elberink 2009; Severino 2008). Two stud-
ied participants with a history of LLR (Golden 2009; Severino
2008); two studied participants with a history of cutaneous SR to
an insect sting (Oude Elberink 2009; Valentine 1990); and three
studied participants with a history of either any SR or anaphylaxis
(Brown 2003; Hunt 1978; Oude Elberink 2006). One study was
restricted to participants allergic to ant stings (Brown 2003); two
studies were restricted to participants allergic to yellowjacket stings
(Oude Elberink 2006; Oude Elberink 2009); one, to honeybee
(Severino 2008); and three studies included participants allergic to
a range of insect stings. One trial studied sublingual immunother-
apy (Severino 2008), and the other six studied subcutaneous im-
munotherapy. The duration of treatment was less than a year in
four studies (Brown 2003; Golden 2009; Hunt 1978; Severino
2008) and a year or longer in three studies (Oude Elberink 2006;
Oude Elberink 2009; Valentine 1990). Four studies (Brown 2003;
Golden 2009; Hunt 1978; Severino 2008) assessed rates of SR
by sting challenge, and three studies (Oude Elberink 2006; Oude
Elberink 2009; Valentine 1990) assessed rates of SR by recording
of accidental field stings.
Excluded studies
Reasons for rejecting the other 21 titles were as follows: no appro-
priate control group (15), not a randomised controlled trial (5),
not VIT (1). Please see the ’Characteristics of excluded studies’
tables.
Risk of bias in included studies
Full details are shown in the ’Characteristics of included studies’
tables. Please see the ’Risk of bias’ graph (review authors’ judge-
ments about each ’Risk of bias’ itempresented as percentages across
all included studies) (Figure 1) and the ’Risk of bias’ summary (re-
view authors’ judgements about each ’Risk of bias’ item for each
included study) (Figure 2).
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Random sequence generation
There was a low risk of bias related to random sequence generation
in five studies (Brown 2003; Hunt 1978; Oude Elberink 2006;
Oude Elberink 2009; Severino 2008), unclear risk in one study
(Valentine 1990), and high risk in one study (Golden 2009).
Allocation
There was a low risk of bias related to allocation concealment in
three studies (Brown 2003; Oude Elberink 2006; Oude Elberink
2009), where a third party was used for treatment allocation. We
judged there was an unclear risk in three studies (Hunt 1978;
Severino 2008; Valentine 1990) due to insufficient information
provided, and a high risk in one study (Golden 2009) due to use
of a predictable sequence for randomisation.
Blinding
There was a low risk of bias related to blinding in one study
(Severino 2008), an unclear risk in one study (Brown 2003), and a
high risk in five studies (Golden 2009;Hunt 1978; Oude Elberink
2006; Oude Elberink 2009; Valentine 1990) due to absent blind-
ing of physicians or outcome assessors.
In the study with unclear risk related to blinding, the reason was
that 12 of 35 VIT-treated participants were unblinded prior to the
assessment of the primary outcome measure, following an interim
analysis (Brown 2003). However, this did not clearly introduce a
risk of bias into the study because outcomes were similar in this
group to those who remained blinded.
Incomplete outcome data
There was a low risk of bias related to incomplete outcome data
in six studies where loss to follow up rates were low (Brown 2003;
Golden 2009; Hunt 1978; Oude Elberink 2006; Oude Elberink
2009; Severino 2008). In one study, loss to follow up rates were
unclear (Valentine 1990).
Selective reporting
There was a low risk of bias related to selective reporting of out-
comes in five studies where the specified outcomes in the method-
ology were reported in the results (Brown 2003; Golden 2009;
Oude Elberink 2006; Oude Elberink 2009; Severino 2008), and
for two studies this was unclear (Hunt 1978; Valentine 1990).
Other potential sources of bias
In 1 study, there was a significant risk of bias because the primary
outcome measure was not assessed in 8 of 20 placebo-treated par-
ticipants, due to safety concerns after an interim analysis (Hunt
1978). In the other studies, there was a low risk of other potential
bias.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Systemic reaction to field or challenge sting
Meta-analysis of data from 6 of our 7 included studies (with a
total of 205 participants stung during follow-up) showed that VIT
significantly reduced our primary outcome measure, risk of SR
to an insect sting (RR 0.10, 95% CI 0.03 to 0.28; Analysis 1.1),
with no significant heterogeneity between studies (I² statistic =
0%). Data from just four of the studies (Brown 2003; Hunt 1978;
Severino 2008; Valentine 1990) contributed to this effect estimate,
because there were no systemic reactions to follow-up stings at all
in two studies (Golden 2009; Oude Elberink 2009).
For 124 participants who were stung in 5 studies information was
available on severity of SR. Venom immunotherapy was signifi-
cantly effective for reducing mild SRs (124 stung participants; RR
0.15, 95%CI 0.03 to 0.85; I² statistic = 0%; 2 studies contributed
to effect estimate; Analysis 1.2) and severe SRs (RR 0.05, 95%
CI 0.00 to 0.81; 1 study contributed to effect estimate; Analysis
1.4). The effect of VIT in reducing the risk of moderate SRs (RR
0.06, 95% CI 0.00 to 1.09; 1 study contributed to effect estimate;
Analysis 1.3) or SR needing treatment with adrenaline (RR 0.07,
95% CI 0.00 to 1.12; I² statistic = 43%; 2 studies contributed to
effect estimate; Analysis 1.5) was not statistically significant. The
reason for the significant heterogeneity between study outcomes
was not clear.
In the study by Oude Elberink 2006, no participants treated with
immunotherapy were stung during follow-up, and one participant
in the control group had a severe SR to a sting during follow-
up, requiring treatment with adrenaline. These data could not be
included in a meta-analysis due to absence of follow-up stings in
one treatment arm, but we included them in calculations of ab-
solute risk of systemic reaction. These showed that 3/113 (2.7%)
participants treated with VIT had a subsequent systemic allergic
reaction to a sting, compared with 37/93 (39.8%) untreated par-
ticipants. A summary of the major study findings, including es-
timates of treatment efficacy in populations at different baseline
risk, is shown in Summary of findings for the main comparison.
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In studies that relied on accidental field stings for assessment of risk
of systemic reaction, we also analysed the data using the number
of participants assessed as the denominator in each study. Meta-
analysis of data from all 7 studies (including 367 participants in
this way) showed a similar reduction in risk of SR to an insect
sting in the VIT-treated group (RR 0.11, 95% CI 0.04 to 0.31;
Analysis 2.1) with no significant heterogeneity between studies (I²
statistic = 0%).
Fatal systemic reaction to field or challenge sting
No study reported any fatal SR to a field or challenge sting, so




Five studies reported whether participants had developed a large
local reaction (LLR) to an insect sting at follow-up (Golden
2009; Oude Elberink 2006; Oude Elberink 2009; Severino 2008;
Valentine 1990). Meta-analysis of 4 of these studies with, in total,
111 participants who were stung showed that VIT significantly
reduced the risk of a LLR to insect sting (RR 0.41, 95% CI 0.24
to 0.69; I² statistic = 43%; Analysis 3.1). In the fifth study (Oude
Elberink 2006), no LLR occurred - only one sting in the control
group. The reason for the significant heterogeneity between study
outcomes was not clear.
One study (Severino 2008) also reported smaller LLRs in VIT-
treated participants than placebo-treated participants following a
sting challenge (median LLR size = 8.5 cm in VIT-treated partic-
ipants and 20.5 cm in placebo-treated participants; P = 0.02).
Quality of life outcomes
Two studies reported quality of life using the Vespid Quality of
Life Questionnaire (VQLQ) in 112 participants (Oude Elberink
2006; Oude Elberink 2009). Quality of life was significantly im-
proved after 1 year of VIT compared with no VIT (mean differ-
ence [MD] 1.21 points on a 7-point scale, 95% CI 0.75 to 1.67;
I² statistic = 0%; Analysis 4.1). When analysed as change during
treatment, there was a greater improvement in quality of life after
VIT compared with no VIT (MD 1.30, 95% CI 0.97 to 1.63; I²
statistic = 0%; Analysis 4.2). When analysed as a response rate,
where an improvement of ≥ 0.5 points is regarded as a significant
response to treatment, VIT increased the chance of a significant
quality of life improvement (RR 7.11, 95% CI 3.02 to 16.71; I²
statistic = 0%; Analysis 4.3). The same two studies (Oude Elberink
2006; Oude Elberink 2009) reported participant views of the bur-
den of treatment in both VIT and control arms using a 7-point
scale where a score of 1 to 3 was a positive view of treatment and
a score of 4 to 7 was a negative or neutral view of treatment. In
participants with a history of anaphylactic reaction to yellowjacket
sting, 41 of 43 immunotherapy-treated participants had a posi-
tive overall assessment of their treatment after 1 year, compared
with 19 of 41 participants in the control group (RR 2.01, 95% CI
1.43 to 2.82). In participants with a history of cutaneous SR to
yellowjacket sting, 14 of 15 VIT-treated participants and 5 of 12
participants in the control group had a positive overall assessment
of their treatment at 1 year (RR 2.24, 95% CI 1.13 to 4.43).
Adverse effects
One study reported local reactions to subcutaneous VIT in 29
participants, but there was no statistically significant increase in
risk of local reactions in immunotherapy versus no treatment (RR
9.35, 95% CI 0.59 to 147.09; Analysis 5.1). Six studies reported
systemic reactions to treatment in 285 participants (Brown 2003;
Golden 2009; Hunt 1978; Oude Elberink 2006; Oude Elberink
2009; Severino 2008). Immunotherapy increased the risk of sys-
temic reactions (RR 8.16, 95%CI 1.53 to 43.46; I² statistic = 0%;
2 studies contributed to the effect estimate; Analysis 5.2). One
study reported the number of systemic reactions per participant
and per injection visit in 67 participants (Brown 2003), and it
found a significantly increased risk of systemic reactions in partic-
ipants treated with VIT (MD 1.00 reaction per participant; 95%
CI 0.08 to 1.91; Analysis 5.3) (MD 0.04 systemic reactions per
injection visit; 95% CI 0.01 to 0.07; Analysis 5.4).
Five studies reported data on severity of systemic reactions to VIT
in 246 participants (Brown 2003; Golden 2009; Oude Elberink
2006; Oude Elberink 2009; Severino 2008). When divided by
severity of adverse reaction, VIT did not significantly increase
the risk of mild systemic reaction to treatment (RR 15.58, 95%
CI 0.94 to 259.56; Analysis 5.5), moderate systemic reaction to
treatment (RR 2.74, 95% CI 0.30 to 25.05; Analysis 5.6), se-
vere systemic reaction to treatment (RR 4.58, 95% CI 0.23 to
92.00; Analysis 5.7), or systemic reaction to treatment requiring
adrenaline (RR 6.40, 95% CI 0.83 to 49.21; Analysis 5.8).
We also reviewed adverse events data from11 observational studies
(1446 participants) of Pharmalgen subcutaneous VIT (Carballada
2003; Carballada 2009; Carballada 2010; Fricker 1997; Haeberli
2003; Kalogeromitros 2010; Muller 1989; Muller 1992; Ramirez
1981; Sanchez-Machin 2010; Schiavino 2004), identified as part
of a National Institute for Health and Clinical Excellence Health
Technology Assessment (Hockenhull 2012). Either Pharmalgen
or a closely-related product was used in at least three of the seven
trials of subcutaneous VIT (Oude Elberink 2006; Oude Elberink
2009; Valentine 1990).
The adverse events data from observational studies are shown in
Table 1.
Systemic reactions to treatment occurred in 3.7% to 44.8% of
participants treated with bee VIT. Overall, in the studies assessed,
131/921(14.2%) participants, or 72/3741 (1 in 52) doses, had a
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systemic reaction.
Systemic reactions to treatment occurred in 0% to 11.1% of par-
ticipants treated with wasp VIT. Overall, 8/289 (2.8%) partici-
pants (per dose rate not available) had a systemic reaction.
Systemic reactions to treatment occurred in 0% to 20% of partic-
ipants in reports of mixed groups of bee and wasp venom allergy
treated with VIT. Overall, 6/88 (6.8%) participants, or 33/1520
(1 in 46) doses, had a systemic reaction. These compare with sys-
temic reaction rates of 9.3% participants (Analysis 5.2) and 1 in
25 doses (95% CI 1 in 100, 1 in 14; Analysis 5.4) in the active
arms of the trials.
Large local reactions occurred in 12.7%, 15.2%, and 11.5% of
participants treated with VIT for bee, wasp, and a mixed group,
respectively, at rates of 1 in 105, 1 in 71, and 1 in 13 doses,
respectively.
No observational study or controlled trial reported any fatal ad-
verse reaction, so it was not possible to estimate the fatality risk
associated with VIT.
Subgroup analyses
We undertook 10 planned subgroup analyses and 2 unplanned
subgroup analyses. We did not undertake further sensitivity anal-
yses, because of the small number of trials contributing data to the
analyses and the low level of heterogeneity between trial outcomes
for most analyses.
First, we analysed our primary outcomemeasure, systemic reaction
to a field or challenge sting, in five subgroup analyses. We found
no evidence that the primary outcome differed according to the
following:
• the route of administration of VIT, although the effect of
sublingual immunotherapy when analysed alone was not
statistically significant (subcutaneous VIT: RR 0.08, 95% CI
0.03 to 0.26) (sublingual VIT: RR 0.29, 95% CI 0.01 to 6.50)
(test for subgroup differences: I² statistic = 0%; P = 0.46;
Analysis 6.1);
• age (for 0 to 18 years: RR 0.16, 95% CI 0.02 to 1.21) (for
those aged > 18 years: RR 0.07, 95% CI 0.01 to 0.48) (test for
subgroup differences: I² statistic = 0%; P = 0.58; Analysis 6.2);
• duration of immunotherapy (under 1 year: RR 0.08, 95%
CI 0.02 to 0.28) (1 to 3 years: RR not estimable) (over 3 years:
RR 0.16, 95% CI 0.02 to 1.21) (test for subgroup differences: I²
statistic = 0%; P= 0.56; Analysis 6.3);
• insect species (for the honeybee: RR 0.29, 95% CI 0.01 to
6.50) (for the wasp: RR not estimable) (for the ant: RR 0.04,
95% CI 0.01 to 0.28) (test for subgroup differences: I² statistic =
11.5%; P = 0.29; Analysis 6.4);
• or updosing schedule (for rush/ultra-rush: RR not
estimable) (for weekly/2-weekly dosing: RR 0.08, 95% CI 0.03
to 0.26; Analysis 6.5).
Next, we analysed the risk of a systemic adverse reaction to VIT
in the same five subgroups. We found no evidence that risk of
systemic adverse reaction differed according to the following:
• route of VIT (subcutaneous: RR 8.16, 95% CI 1.53 to
43.46; Analysis 6.6) (sublingual: RR not estimable);
• age (0 to 18 year: RR not estimable) (aged > 18 years: RR
11.89, 95% CI 1.65 to 85.80; Analysis 6.7);
• duration of immunotherapy (under 1 year: RR 8.16, 95%
CI 1.53 to 43.46; Analysis 6.8) (1 to 3 years or over 3 years: RR
not estimable);
• insect species (for the honeybee and wasp: RR not
estimable) (for the ant: RR 11.89, 95% CI 1.65 to 85.80;
Analysis 6.9); or
• updosing schedule (for rush/ultra-rush: RR not estimable)
(for weekly/2-weekly dosing: RR 8.16, 95% CI 1.53 to 43.46;
Analysis 6.10).
In a post-hoc analysis, we found no evidence that the effect of VIT
on risk of SR to an insect sting differed according to history of
prior allergic reaction (RR 0.29, 95% CI 0.01 to 6.50), prior large
local reaction (RR 0.08, 95% CI 0.03 to 0.26) or prior systemic
reaction (test for subgroup differences: I² statistic = 0%; P = 0.46;
Analysis 7.1).
We found a significant risk of systemic adverse reaction to VIT in
those with a prior SR (RR 8.16, 95% CI 1.53 to 43.46; Analysis
7.2) and no reported occurrence of systemic adverse reaction to
VIT in those with a prior LLR.
D I S C U S S I O N
Summary of main results
We identified 7 controlled clinical trials of venom immunother-
apy (VIT) for preventing allergic reactions to insect stings; these
trials included 392 participants with a prior history of allergic re-
action to a sting. The studies included children and adult par-
ticipants allergic to bee, wasp, and ant venom; those with severe
systemic or simple large local reactions to stings; and both sub-
lingual and subcutaneous treatment. Five studies were judged to
have a significant risk of bias (Golden 2009; Hunt 1978; Oude
Elberink 2006; Oude Elberink 2009; Valentine 1990), primarily
due to outcome assessors not being blinded. We found that VIT
significantly reduced the risk of a systemic allergic reaction to a
future insect sting, a finding that was consistent between studies,
although just four studies contributed to the effect estimate for the
primary outcome. The treatment appeared to be effective for pre-
venting allergic reactions of different severity, but we were unable
to establish whether it can prevent fatal allergic reactions, because
of their rarity.
In twonon-blinded studies, VIT resulted in significantly improved
quality of life for participants, by reducing anxiety and limitations
15Venom immunotherapy for preventing allergic reactions to insect stings (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to activities caused by fear of insects, and in these two studies, al-
most all participants treated with VIT had a positive view of their
treatment after one year (Oude Elberink 2006; Oude Elberink
2009). Very few participants in these two studies were stung fol-
lowing treatment, but they experienced an improved quality of life
due to reduced anxiety and reduced restriction of activities related
to fear of being stung. Immunotherapy was associated with a sig-
nificant risk of a systemic adverse reaction to treatment, which oc-
curred in 9.3% of participants treated with VIT in the controlled
trials, reported in 1 trial as a rate of 1 systemic reaction per 25
injections. Analysis of adverse events data from non-randomised
studies of VIT found that 2.8% of participants treated with wasp
VIT and 14.2% treated with bee VIT suffered a systemic adverse
reaction to treatment, with wide variations according to the pop-
ulation studied. There were insufficient data to estimate the risk
of fatal allergic reaction to treatment with VIT.
Subgroup analyses failed to identify a route of immunotherapy,
participant age, duration of immunotherapy, insect species, or up-
dosing schedule with a different efficacy or safety profile, although
data were limited for many of these analyses by the small numbers
of events.
Overall completeness and applicability of
evidence
We found clear evidence for the efficacy of VIT in preventing
further allergic reactions to insect stings. While the methodolog-
ical quality of the studies was mixed, this finding was consistent
across studies. It is uncertain whether this treatment can prevent
fatal sting anaphylaxis, because of the rarity of that outcome, but
there was an improved quality of life associated with treatment.
We found adverse reaction rates were significant, and these varied
in the observational studies according to insect species and patient
population. For many people with a history of systemic reaction
(SR) to an insect sting, the annual risk of a further sting from
the same insect is relatively low (Hockenhull 2012). The decision
to undertake VIT clearly needs careful assessment of the risk of
a further insect sting occurring, a person’s quality of life impair-
ment and treatment preference, and the risk of a systemic adverse
reaction to treatment for a particular insect species.
Quality of the evidence
The results of this review are based on analysis of relatively few
trials and participants, but they are consistent for the primary
outcome measure and some secondary outcomes.
We included one quasi-randomised trial (Golden 2009), and the
issue of whether to include quasi-randomised trials was not specif-
ically considered at the protocol stage. The quasi-randomised na-
ture of the trial only came to light in correspondence with the
study authors after we had completed data analysis. Therefore, we
elected to keep this study in the review, although its inclusion or
exclusion does not significantly change the main study outcomes.
The value of the planned subgroup analyses was limited by small
numbers of events in many cases. Further work is needed to estab-
lish whether there are differential benefits for VIT, in particular,
patient groups or using particularmodes of delivery. Thismay help
to establish evidence-based indications for initiating treatment. In
particular, we only identified one trial of sublingual VIT; while
this type of treatment may carry a reduced risk of systemic adverse
reactions (Radulovic 2011), its clinical efficacy still needs to be
investigated further. We excluded studies of whole body extract
immunotherapy from the review, and a separate review of this in-
tervention is warranted (Freeman 1992). We only identified two
trials of VIT in participants with a prior history of LLR without
systemic reaction to an insect sting, and it is not clear whether
VIT is effective for preventing future systemic reactions in these
participants. Other areas for further research are the optimal main-
tenance dose, dosing interval, and treatment duration.
Potential biases in the review process
The strengths of this review were the consistency of results over
a wide variety of settings, patient groups, insect species, and to
a limited extent, over different modes of treatment delivery and
the high proportion of original data acquired from study authors.
Thesemeant that the review has clear-cut findings, but the absence
of blinding in some of the included studies and the relatively short
follow-up period in most of them should be noted.
Agreements and disagreements with other
studies or reviews
One other systematic review of VIT has been undertaken (
Watanabe 2010). It was limited to subcutaneous VIT and only
identified three of the trials that we included. It was also com-
plicated by considering two separate publications describing out-
comes in participants from the same trial as two separate RCTs
(Valentine 1990), which means their meta-analysis was flawed.
Nevertheless, they found that VIT reduces the risk of systemic re-
actions to an insect sting (odds ratio 0.29, 95% CI 0.10 to 0.87),
and their conclusion that the risk-benefit should be assessed in
each case before initiating VIT is consistent with our conclusions.
They did not address adverse effects in detail. Our findings that
VIT is an effective treatment for allergy to insect stings are consis-
tent with British, European, and North American practice guide-
lines (Bonifazi 2005; Golden 2011; Krishna 2011). The statement
that VIT is not indicated for children with a history of systemic
reactions limited to cutaneous involvement is included in some
reviews and guidelines (Golden 2011; Krishna 2011; Watanabe
2010), but not others (Bonifazi 2005). This statement is based on
the findings of 1 observational study that 12 of 89 (13%) such
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children who declined VIT treatment had a systemic reaction to
a field sting during long-term follow-up, but no cases of severe
systemic reaction were noted (Golden 2004).
Our findings suggest that quality of life improvement may be a
valid indication for VIT in some such cases (Bonifazi 2005), and
that in all cases, an assessment must be made of likelihood of a
future sting, of a future sting reaction, and of an allergic reaction
to treatment. A recentHealth Technology Assessment of oneman-
ufacturer’s VIT products concluded that VIT may only be cost
effective for preventing systemic reactions in those at risk of > five
insect stings per year, which would exclude most people with a
previous systemic reaction to a sting from treatment (Hockenhull
2012). However, the treatment is likely to be cost effective for im-
proving quality of life in a wider group of people, and this needs
further study.While this and other forms of allergen immunother-
apy have generally been proven to be clinically effective, there is a
need for more data describing effects on overall quality of life and
health economic outcomes and long-term outcomes beyond the
treatment period (Calderon 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In those who have had a previous allergic reaction to an insect
sting, venom immunotherapy (VIT) using extracted insect venom
is effective for preventing a further allergic reaction to a future
sting and improves people’s quality of life.
There is a significant risk of systemic allergic reaction to VIT dur-
ing treatment, but this differs across insect species and popula-
tions.
The decision whether to initiate VIT depends on an accurate di-
agnosis, followed by careful assessment of a person’s risk of further
insect sting reactions, their quality of life, and their risk of a sys-
temic reaction to VIT.
Implications for research
Further research is needed to identify the patient groups who ben-
efitmost from this treatment, and the optimal treatment duration.
Future trials in this area should include quality of life and health
economic outcomes.
Future trials should investigate modes of VIT, which may carry a
reduced risk of systemic allergic reaction, particularly sublingual
treatment, and outcome assessors should be blinded to treatment
allocation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2003
Methods This was a randomised, double-blind, placebo-controlled, parallel-group trial
Participants This trial was conducted in Australia.
The participants were adults aged 18 to 63 years.
The total number of participants was 68.
The total number of participants in the treatment group was 35 (22 men)
The total number of participants in the control group was 33 (18 men)
The species of insect venom that the participants were allergic to was Myrmecia pilosula
(M. pilosula) venom (ant venom).
Inclusion criteria of the trial
• History of 1 or more Mueller grade II to IV reactions to ant venom (M. pilosula)
and a positive intradermal skin test to M. pilosula venom
Exclusion criteria of the trial
• ACE inhibitor or β-blockers therapy
• Hypertension
• Heart disease
• Poorly-controlled lung disease
• People with negative skin tests
Interventions • Treatment: subcutaneous injections of VIT
VIT Manufacturer: NSL Health Ltd., Melbourne, Australia
Duration: 4 to 5 months
Updosing: Outpatient cluster hyposensitisation regimen (10 visits)
Maintenance dose: 100 µg monthly
• Control: subcutaneous placebo (histamine acid phosphate)
Outcomes Outcomes of the trial
1. Systemic reaction to insect sting challenge
2. Fatal systemic reaction to insect sting challenge
3. Adverse events to immunotherapy
Notes This study was funded by NSL Health Ltd. (VIT manufacturer), the Department of
Health and Human Services Tasmania, and Royal Hobart Research Foundation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number-based sequential alloca-
tion was done by a third party
Allocation concealment (selection bias) Low risk This was done by a third party.
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Brown 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants lost to follow up or excluded
were accounted for along with participants
followed to designated follow-up periods
(0 out of 35 participants in the treatment
group and 4 out of 33 participants in the
control group)
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results section
Other bias Low risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Packs were identical in appearance, and
contents containing placebo or lyophilised
venom were dispensed. Early unblinding
meant that 12 of 35 VIT-treated partic-
ipants were unblinded at the time of the
sting challenge; however, outcomes were
similar in this group to the other 23 who
had blinded sting challenges
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessors were blinded.
Golden 2009
Methods This was a quasi-randomised, open-label, controlled, parallel-group trial
Participants This trial was conducted in the USA.
The participants were adults aged 21 to 63 years.
The total number of participants was 29.
The total number of participants in the treatment group was 19
The total number of participants in the control group was 10
No distribution by gender was reported.
The species of insect venoms that the participants were allergic to were honeybee (7),
yellowjacket (2), polistes wasp (2), and mixed vespid (18)
Inclusion criteria of the trial
• History of a large local reaction to insect sting
• Wheal > 5 mm and erythema > 10 mm in intradermal test and local induration of
≥ 16 cm in a sting challenge
Exclusion criteria of the trial
• Use of β-blockers medication
• Pregnancy or insufficient measures to avoid pregnancy and previous sting
anaphylaxis or VIT
• Uncontrolled asthma or other medical conditions that might affect the risk or
outcome of anaphylaxis
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Golden 2009 (Continued)
Interventions • Treatment: subcutaneous injections of VIT
VIT Manufacturer: ALK-Abelló
Duration: 12 weeks
Updosing: Used a dose schedule to achieve the maintenance dose in 7 weekly visits
Maintenance dose: 100 µg every 4 weeks
• Control: no treatment
Outcomes Outcomes of the trial
1. Systemic reaction to insect sting challenge
2. Fatal systemic reaction to insect sting challenge
3. Large local reactions to insect sting challenge (measured by participants at home using
study measuring equipment)
4. Adverse events to immunotherapy
Notes This study was funded by the National Institutes of Health and ALK-Abelló (VIT
manufacturer)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation was done based on se-
quence of enrolment, probably using al-
ternation - therefore, this was a quasi-ran-
domised study
Allocation concealment (selection bias) High risk This was inadequate.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow up during
the 12-week period.
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results section
Other bias Low risk No other sources of bias were detected or
suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded.
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Hunt 1978
Methods This was a randomised, single-blind, placebo-controlled, parallel-group trial
Participants This trial was conducted in the USA.
The participants were adults and children aged 15 to 69 years
The total number of participants was 39.
The total number of participants in the treatment group was 19
The total number of participants in the control group was 20
No distribution by gender was reported.
The species of insect venoms that the participants were allergic to were honeybee, yel-
lowjacket, yellow hornet, and white-faced hornet
Inclusion criteria of the trial
• History of generalised allergic reactions to insect sting and positive skin test
Exclusion criteria of the trial
• Unclear
Interventions • Treatment: subcutaneous injections of VIT
VIT Manufacturer: not stated
Duration: 6 to 10 weeks
Updosing: Cluster updosing (modified rush protocol) weekly
Maintenance dose: 100 µg weekly
• Control: subcutaneous placebo (histamine solution)
Outcomes Outcomes of the trial
1. Systemic reaction to insect sting challenge
2. Fatal systemic reaction to insect sting challenge
3. Adverse events to immunotherapy
Notes This study was funded by the US’ National Institute of Allergy and Infectious Diseases
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned a treatment reg-
imen by drawing lots
Allocation concealment (selection bias) Unclear risk Insufficient details were provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 of the 19 participants in the treat-
ment group was lost to follow up (did not
toleratemaintenance dose). None of the 20
participants in the control group were lost
to follow up
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias High risk Only 12 of 20 participants in the placebo
group underwent sting challenge due to
cessation of placebo group challenges on
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Hunt 1978 (Continued)
safety grounds
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were blinded, but the physi-
cians were not.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The clinician and outcome assessor were
not blinded.
Oude Elberink 2006
Methods This was a randomised, open-label, controlled, parallel-group trial
Participants This trial was conducted in the Netherlands.
The participants were adults aged 18 to 65 years.
The total number of participants was 91.
The total number of participants in the treatment group was 47
The total number of participants in the control group was 44
No distribution by gender was reported.
The species of insect venom that the participants were allergic to was yellowjacket
Inclusion criteria of the trial
• History of 1 or more anaphylactic reactions after yellowjacket stings and positive
intradermal or serum IgE test
Exclusion criteria of the trial
• β-blocker therapy or if there was a need to carry an EpiPen for other reasons
• Mastocytosis
• Serious medical or surgical illness
• Pregnancy
Interventions • Treatment: subcutaneous injections of VIT
VIT Manufacturer: ALK-Abelló
Duration: 1 year
Updosing: Modified semi-rush schedule over approximately 6 weeks
Maintenance dose: 100 µg every 6 weeks
• Control: EpiPen
Outcomes Outcomes of the trial
1. Systemic reaction to accidental insect sting
2. Quality of life assessment using “Burden of Treatment” questionnaire at 1 year
Notes This is part of the same study reported in theOude Elberink 2001 and 2002 publications.
This study was funded by ALK-Abelló (VIT manufacturer)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Oude Elberink 2006 (Continued)
Random sequence generation (selection
bias)
Low risk A minimisation computer program was
used. Participantswere stratified for age and
time of reaction
Allocation concealment (selection bias) Low risk This was done by a third party.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 of 47 participants were lost to follow up
in the treatment group; 3 of 44 participants
were lost to follow up in the control group
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were either reported in the results sec-
tion or provided by the authors as the orig-
inal dataset
Other bias Low risk No other sources of bias were detected or
suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded.
Oude Elberink 2009
Methods This was a randomised, open-label, controlled, parallel-group trial
Participants This trial was conducted in the Netherlands.
The participants were adults aged 18 years and older.
The total number of participants was 29.
The total number of participants in the treatment group was 15 (9 men)
The total number of participants in the control group was 14 (6 men)
The species of insect venom that the participants were allergic to was yellowjacket
Inclusion criteria of the trial
• 1 or more dermal reactions following yellowjacket stings and positive intradermal
or serum IgE test
Exclusion criteria of the trial
• β-blocker therapy or if there was a need to carry an EpiPen for other reasons
• Mastocytosis
• Serious medical or surgical illness
• Pregnancy
Interventions • Treatment: subcutaneous injections of VIT
VIT Manufacturer: ALK-Abelló
Duration: 1 year
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Oude Elberink 2009 (Continued)
Updosing: Modified semi-rush schedule
Maintenance dose:100 µg every 6 weeks
• Control: EpiPen
Outcomes Outcomes of the trial
1. Quality of life assessment using the Vespid Quality of Life Questionnaire (VQLQ) at
1 year
Notes This study was funded by ALK-Abelló (VIT manufacturer).
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A minimisation computer program was
used. Participantswere stratified for age and
time of reaction
Allocation concealment (selection bias) Low risk This was done by a third party.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants lost to follow up or excluded
were accounted for along with participants
followed to designated follow-up periods.
None of the 15 participants in the treat-
ment group, and 1 of 14 in the control
group were lost to follow up
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results section
Other bias Low risk No other sources of bias were detected or
suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded.
Severino 2008
Methods This was a randomised, double-blind, placebo-controlled, parallel-group trial
Participants This trial was conducted in Italy.
The participants were adults aged 18 years and older.
The total number of participants was 30.
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Severino 2008 (Continued)
The total number of participants in the treatment group was 15 (10 men)
The total number of participants in the control group was 15 (12 men)
The species of insect venom that the participants were allergic to was honeybee
Inclusion criteria of the trial
• History of large local reaction (LLR; defined in this study as ≥ 10 cm for ≥ 24
hours) after honeybee stings without any evidence of previous systemic reactions
• Positive skin test
• Positive serum specific IgE test and qualifying sting challenge
Exclusion criteria of the trial
• Participants with sensitisations to multiple venoms other than honeybee venom
• Previous systemic reaction to honeybee sting
• Cardiovascular diseases
• Systemic immunologic disorders
• Malignancies
• Allergic asthma
• Lesions of the oral mucosa
• Pregnancy
Interventions • Treatment: sublingual drop VIT (administered in the morning before breakfast,
keeping it under the tongue for 2 minutes before swallowing)
VIT Manufacturer: Anallergo SpA, Florence, Italy
Duration: 6 months
Updosing: Build up regimen by gradually administering increasing amounts of venom,
starting from 0.05 to 35 µg per day over 33 days
Maintenance dose: 35 µg taken on alternate days with cumulative dose of 525 µg of
venom monthly
• Control: sublingual placebo (same preparation as active treatment but without the
allergen)
Outcomes Outcomes of the trial
1. Systemic reaction to insect sting challenge
2. Fatal systematic reaction to insect sting challenge
3. Adverse events to immunotherapy
4. Large local reactions to insect sting challenge
Notes This study was funded by Anallergo SpA (VIT manufacturer).
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwasmade using a computer
list.
Allocation concealment (selection bias) Unclear risk Insufficient details were provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was a low loss to follow up rate - just
1 out of 15 participants in the treatment
group and 3 out of 15 participants in the
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Severino 2008 (Continued)
control group were not assessed for the pri-
mary outcome measure; all were due to re-
fusal to undergo the sting challenge
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results section
Other bias Low risk No other sources of bias were detected or
suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Valentine 1990
Methods This was a randomised, open-label, controlled, parallel-group trial
Participants This trial was conducted in the USA.
The participants were children aged 2 to 16 years.
The total number of participants was 106.
The total number of participants in the treatment group was 45 (70% men)
The total number of participants in the control group was 61 (75% men)
It was unclear how many participants were lost to follow up.
The species of insect venoms that the participants were allergic to were honeybee, yel-
lowjacket, yellow hornet, white-faced hornet, and Polistes.
Inclusion criteria of the trial
• Children with history of systemic insect sting reaction confined to skin and a
positive skin test
Exclusion criteria of the trial
• Children with more severe reaction to insect sting (hoarseness, dyspnoea,
wheezing, or lightheadedness)




Maintenance dose: 100 µg monthly
• Control: no treatment
Outcomes Outcomes of the trial
1. Systemic reaction to accidental (field) insect sting
2. Large local reactions to accidental insect sting
3. Both recorded at periodic study visits using a structured questionnaire
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Valentine 1990 (Continued)
Notes This study included the participants reported in the study of Schuberth 1983
This study was funded by the National Institutes of Health and a Pfizer Biomedical
research award
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details were provided.
Allocation concealment (selection bias) Unclear risk No details were provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It was unclear how many participants were
lost to follow up.
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Low risk No other sources of bias were detected or
suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berchtold 1992 There was no appropriate control group.
Bilo 2009 There was no appropriate control group.
Bousquet 1987 This was not a trial of venom immunotherapy.
Brockow 1997 There was no appropriate control group.
Brown 2008 There was no appropriate control group.
Divanovic 1997 There was no appropriate control group.
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(Continued)
Malling 1985 This was not a randomised controlled trial.
Mosbech 1986 There was no appropriate control group.
Muller 1985 There was no appropriate control group.
Muller 1987 There was no appropriate control group.
Muller 1992 This was not a randomised controlled trial.
Muller 2001 There was no appropriate control group.
Muller 2008 There was no appropriate control group.
Ohman 1986 This was not a randomised controlled trial.
Quercia 2001 There was no appropriate control group.
Reimers 2000 There was no appropriate control group.
Roumana 2009 There was no appropriate control group.
Spertini 2000 This was not a randomised controlled trial.
Thurnheer 1983 There was no appropriate control group.
Wohrl 2007 There was no appropriate control group.
Zubrinich 2010 This was not a randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Risk of systemic reaction - Immunotherapy versus control




participants Statistical method Effect size
1 Any systemic reaction to field or
challenge sting
6 205 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.28]
2 Mild systemic reaction to field
or challenge sting
4 124 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.03, 0.85]
3 Moderate systemic reaction to
field or challenge sting
4 124 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.00, 1.09]
4 Severe systemic reaction to field
or challenge sting
4 124 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.81]
5 Systemic reaction to field or
challenge sting requiring
adrenaline treatment
4 124 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.12]
Comparison 2. Risk of systemic reaction - Analysed by number treated




participants Statistical method Effect size
1 Any systemic reaction to field or
challenge sting
7 367 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.04, 0.31]
Comparison 3. Risk of local reaction - Immunotherapy versus control




participants Statistical method Effect size
1 Large local reaction to field or
challenge sting
4 111 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.24, 0.69]
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Comparison 4. Quality of life - Immunotherapy versus control




participants Statistical method Effect size
1 Vespid Quality of Life
Questionnaire - end of
treatment
2 112 Mean Difference (IV, Random, 95% CI) 1.21 [0.75, 1.67]
2 Vespid Quality of Life
Questionnaire - change during
treatment
2 112 Mean Difference (IV, Random, 95% CI) 1.30 [0.97, 1.63]
3 Vespid Quality of Life
Questionnaire - response rate
2 112 Risk Ratio (M-H, Random, 95% CI) 7.11 [3.02, 16.71]
Comparison 5. Adverse reaction to treatment - Immunotherapy versus control




participants Statistical method Effect size
1 Any local reaction 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Any systemic reaction 6 285 Risk Ratio (M-H, Random, 95% CI) 8.16 [1.53, 43.46]
3 Number of systemic reactions
per participant
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Number of systemic reactions
per visit
1 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Mild systemic reaction 5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Moderate systemic reaction 5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Severe systemic reaction 5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Systemic reaction requiring
adrenaline treatment
5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Planned subgroup analyses - Immunotherapy versus control




participants Statistical method Effect size
1 Systemic reaction to field or
challenge sting by route of
immunotherapy
6 205 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.28]
1.1 Subcutaneous
immunotherapy
5 179 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.03, 0.26]
1.2 Sublingual
immunotherapy
1 26 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.50]
2 Systemic reaction to field or
challenge sting by age
5 175 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.35]
2.1 Under 18 years 1 51 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.21]
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2.2 Aged 18 years or over 4 124 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.48]
3 Systemic reaction to field or
challenge sting by duration of
immunotherapy
6 205 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.28]
3.1 Under 1 year of treatment 4 149 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.02, 0.28]
3.2 1 to 3 years of treatment 1 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Over 3 years of treatment 1 51 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.21]
4 Systemic reaction to field or
challenge sting by insect species
3 95 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.48]
4.1 Honey bee 1 26 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.50]
4.2 Wasp 1 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Ant 1 64 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.01, 0.28]
5 Systemic reaction to field or
challenge sting by updosing
schedule
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Rush or ultrarush 1 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Weekly or 2-weekly 4 174 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.03, 0.26]
6 Systemic adverse reaction
to treatment by route of
immunotherapy
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Subcutaneous
immunotherapy
5 255 Risk Ratio (M-H, Random, 95% CI) 8.16 [1.53, 43.46]
6.2 Sublingual
immunotherapy
1 30 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Systemic adverse reaction to
treatment by age
5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Under 18 years 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Aged 18 years or over 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Systemic adverse reaction to
treatment by duration of
immunotherapy
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Under 1 year of treatment 4 165 Risk Ratio (M-H, Random, 95% CI) 8.16 [1.53, 43.46]
8.2 1 to 3 years of treatment 2 120 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Over 3 years of treatment 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Systemic adverse reaction to
treatment by insect species
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Honey bee 1 30 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Wasp 2 120 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Ant 1 67 Risk Ratio (M-H, Random, 95% CI) 11.89 [1.65, 85.80]
10 Systemic adverse reaction to
treatment by updosing schedule
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Rush or ultrarush 2 120 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Weekly or 2-weekly 3 135 Risk Ratio (M-H, Random, 95% CI) 8.16 [1.53, 43.46]
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Comparison 7. Unplanned subgroup analyses - Immunotherapy versus control




participants Statistical method Effect size
1 Systemic reaction to field or
challenge sting by history of
prior systemic reaction
6 205 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.28]
1.1 No prior systemic reaction
to insect sting
2 55 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.50]
1.2 Prior systemic reaction to
insect sting
4 150 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.03, 0.26]
2 Systemic adverse reaction to
treatment by history of prior
systemic reaction
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 No prior systemic reaction
to insect sting
2 59 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Prior systemic reaction to
insect sting
4 226 Risk Ratio (M-H, Random, 95% CI) 8.16 [1.53, 43.46]
Analysis 1.1. Comparison 1 Risk of systemic reaction - Immunotherapy versus control, Outcome 1 Any
systemic reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 1 Risk of systemic reaction - Immunotherapy versus control
Outcome: 1 Any systemic reaction to field or challenge sting








Brown 2003 1/35 21/29 30.3 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/18 7/12 29.8 % 0.10 [ 0.01, 0.68 ]
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 1/12 11.8 % 0.29 [ 0.01, 6.50 ]
Valentine 1990 1/24 7/27 28.1 % 0.16 [ 0.02, 1.21 ]
Total (95% CI) 113 92 100.0 % 0.10 [ 0.03, 0.28 ]
Total events: 3 (Immunotherapy), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.28 (P = 0.000018)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 1.2. Comparison 1 Risk of systemic reaction - Immunotherapy versus control, Outcome 2 Mild
systemic reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 1 Risk of systemic reaction - Immunotherapy versus control
Outcome: 2 Mild systemic reaction to field or challenge sting








Brown 2003 1/35 7/29 70.0 % 0.12 [ 0.02, 0.91 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 1/12 30.0 % 0.29 [ 0.01, 6.50 ]
Total (95% CI) 71 53 100.0 % 0.15 [ 0.03, 0.85 ]
Total events: 1 (Immunotherapy), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 1.3. Comparison 1 Risk of systemic reaction - Immunotherapy versus control, Outcome 3
Moderate systemic reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 1 Risk of systemic reaction - Immunotherapy versus control
Outcome: 3 Moderate systemic reaction to field or challenge sting








Brown 2003 0/35 6/29 100.0 % 0.06 [ 0.00, 1.09 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 0/12 Not estimable
Total (95% CI) 71 53 100.0 % 0.06 [ 0.00, 1.09 ]
Total events: 0 (Immunotherapy), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 1.4. Comparison 1 Risk of systemic reaction - Immunotherapy versus control, Outcome 4 Severe
systemic reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 1 Risk of systemic reaction - Immunotherapy versus control
Outcome: 4 Severe systemic reaction to field or challenge sting








Brown 2003 0/35 8/29 100.0 % 0.05 [ 0.00, 0.81 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 0/12 Not estimable
Total (95% CI) 71 53 100.0 % 0.05 [ 0.00, 0.81 ]
Total events: 0 (Immunotherapy), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 1.5. Comparison 1 Risk of systemic reaction - Immunotherapy versus control, Outcome 5
Systemic reaction to field or challenge sting requiring adrenaline treatment.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 1 Risk of systemic reaction - Immunotherapy versus control
Outcome: 5 Systemic reaction to field or challenge sting requiring adrenaline treatment








Brown 2003 0/35 19/29 53.4 % 0.02 [ 0.00, 0.34 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 1/12 46.6 % 0.29 [ 0.01, 6.50 ]
Total (95% CI) 71 53 100.0 % 0.07 [ 0.00, 1.12 ]
Total events: 0 (Immunotherapy), 20 (Control)
Heterogeneity: Tau2 = 1.68; Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 2.1. Comparison 2 Risk of systemic reaction - Analysed by number treated, Outcome 1 Any
systemic reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 2 Risk of systemic reaction - Analysed by number treated
Outcome: 1 Any systemic reaction to field or challenge sting








Brown 2003 1/35 21/29 27.5 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/18 7/12 27.0 % 0.10 [ 0.01, 0.68 ]
Oude Elberink 2006 0/43 1/41 10.3 % 0.32 [ 0.01, 7.59 ]
Oude Elberink 2009 0/15 0/13 Not estimable
Severino 2008 0/14 1/12 10.7 % 0.29 [ 0.01, 6.50 ]
Valentine 1990 1/45 7/61 24.5 % 0.19 [ 0.02, 1.52 ]
Total (95% CI) 189 178 100.0 % 0.11 [ 0.04, 0.31 ]
Total events: 3 (Immunotherapy), 37 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.30, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000029)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
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Analysis 3.1. Comparison 3 Risk of local reaction - Immunotherapy versus control, Outcome 1 Large local
reaction to field or challenge sting.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 3 Risk of local reaction - Immunotherapy versus control
Outcome: 1 Large local reaction to field or challenge sting








Golden 2009 9/19 7/10 32.4 % 0.68 [ 0.36, 1.26 ]
Oude Elberink 2009 1/3 2/2 12.0 % 0.45 [ 0.12, 1.76 ]
Severino 2008 5/14 12/12 30.1 % 0.38 [ 0.19, 0.75 ]
Valentine 1990 5/24 25/27 25.6 % 0.23 [ 0.10, 0.49 ]
Total (95% CI) 60 51 100.0 % 0.41 [ 0.24, 0.69 ]
Total events: 20 (Immunotherapy), 46 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 5.31, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 3.31 (P = 0.00093)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Quality of life - Immunotherapy versus control, Outcome 1 Vespid Quality of
Life Questionnaire - end of treatment.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 4 Quality of life - Immunotherapy versus control
Outcome: 1 Vespid Quality of Life Questionnaire - end of treatment





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Oude Elberink 2006 43 5.2483 (1.13053) 41 4.1 (1.36358) 73.1 % 1.14 [ 0.61, 1.68 ]
Oude Elberink 2009 15 5.8372 (1.18242) 13 4.46 (1.1999) 26.9 % 1.38 [ 0.49, 2.26 ]
Total (95% CI) 58 54 100.0 % 1.21 [ 0.75, 1.67 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.15 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Quality of life - Immunotherapy versus control, Outcome 2 Vespid Quality of
Life Questionnaire - change during treatment.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 4 Quality of life - Immunotherapy versus control
Outcome: 2 Vespid Quality of Life Questionnaire - change during treatment





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Oude Elberink 2006 43 0.9539 (1.05382) 41 -0.38 (0.87623) 64.3 % 1.33 [ 0.92, 1.75 ]
Oude Elberink 2009 15 0.8339 (0.87802) 13 -0.41 (0.61105) 35.7 % 1.25 [ 0.69, 1.80 ]
Total (95% CI) 58 54 100.0 % 1.30 [ 0.97, 1.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 7.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Quality of life - Immunotherapy versus control, Outcome 3 Vespid Quality of
Life Questionnaire - response rate.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 4 Quality of life - Immunotherapy versus control
Outcome: 3 Vespid Quality of Life Questionnaire - response rate








Oude Elberink 2006 30/43 4/41 80.6 % 7.15 [ 2.76, 18.52 ]
Oude Elberink 2009 8/15 1/13 19.4 % 6.93 [ 0.99, 48.33 ]
Total (95% CI) 58 54 100.0 % 7.11 [ 3.02, 16.71 ]
Total events: 38 (Immunotherapy), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 1
Any local reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 1 Any local reaction








Golden 2009 8/19 0/10 9.35 [ 0.59, 147.09 ]
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Analysis 5.2. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 2
Any systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 2 Any systemic reaction








Brown 2003 13/35 1/32 71.6 % 11.89 [ 1.65, 85.80 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/19 0/20 28.4 % 3.15 [ 0.14, 72.88 ]
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
Total (95% CI) 150 135 100.0 % 8.16 [ 1.53, 43.46 ]
Total events: 14 (Immunotherapy), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 3
Number of systemic reactions per participant.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 3 Number of systemic reactions per participant





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2003 1.028571 (2.759856) 35 32 0.03 (0.176777) 1.00 [ 0.08, 1.91 ]
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Analysis 5.4. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 4
Number of systemic reactions per visit.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 4 Number of systemic reactions per visit





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2003 0.0407677 (0.084119) 35 32 0 (0.019642) 0.04 [ 0.01, 0.07 ]
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Analysis 5.5. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 5
Mild systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 5 Mild systemic reaction








Brown 2003 8/35 0/32 15.58 [ 0.94, 259.56 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
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Analysis 5.6. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 6
Moderate systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 6 Moderate systemic reaction








Brown 2003 3/35 1/32 2.74 [ 0.30, 25.05 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
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Analysis 5.7. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 7
Severe systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 7 Severe systemic reaction








Brown 2003 2/35 0/32 4.58 [ 0.23, 92.00 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
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Analysis 5.8. Comparison 5 Adverse reaction to treatment - Immunotherapy versus control, Outcome 8
Systemic reaction requiring adrenaline treatment.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 5 Adverse reaction to treatment - Immunotherapy versus control
Outcome: 8 Systemic reaction requiring adrenaline treatment








Brown 2003 7/35 1/32 6.40 [ 0.83, 49.21 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
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Analysis 6.1. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 1
Systemic reaction to field or challenge sting by route of immunotherapy.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 1 Systemic reaction to field or challenge sting by route of immunotherapy









Brown 2003 1/35 21/29 30.3 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/18 7/12 29.8 % 0.10 [ 0.01, 0.68 ]
Oude Elberink 2009 0/3 0/2 Not estimable
Valentine 1990 1/24 7/27 28.1 % 0.16 [ 0.02, 1.21 ]
Subtotal (95% CI) 99 80 88.2 % 0.08 [ 0.03, 0.26 ]
Total events: 3 (Immunotherapy), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000019)
2 Sublingual immunotherapy
Severino 2008 0/14 1/12 11.8 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 14 12 11.8 % 0.29 [ 0.01, 6.50 ]
Total events: 0 (Immunotherapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 113 92 100.0 % 0.10 [ 0.03, 0.28 ]
Total events: 3 (Immunotherapy), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.28 (P = 0.000018)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 6.2. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 2
Systemic reaction to field or challenge sting by age.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 2 Systemic reaction to field or challenge sting by age








1 Under 18 years
Valentine 1990 1/24 7/27 40.0 % 0.16 [ 0.02, 1.21 ]
Subtotal (95% CI) 24 27 40.0 % 0.16 [ 0.02, 1.21 ]
Total events: 1 (Immunotherapy), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
2 Aged 18 years or over
Brown 2003 1/35 21/29 43.2 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2009 0/3 0/2 Not estimable
Severino 2008 0/14 1/12 16.9 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 71 53 60.0 % 0.07 [ 0.01, 0.48 ]
Total events: 1 (Immunotherapy), 22 (Control)
Heterogeneity: Tau2 = 0.34; Chi2 = 1.19, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 2.74 (P = 0.0062)
Total (95% CI) 95 80 100.0 % 0.10 [ 0.03, 0.35 ]
Total events: 2 (Immunotherapy), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.58), I2 =0.0%
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Analysis 6.3. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 3
Systemic reaction to field or challenge sting by duration of immunotherapy.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 3 Systemic reaction to field or challenge sting by duration of immunotherapy








1 Under 1 year of treatment
Brown 2003 1/35 21/29 30.3 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/18 7/12 29.8 % 0.10 [ 0.01, 0.68 ]
Severino 2008 0/14 1/12 11.8 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 86 63 71.9 % 0.08 [ 0.02, 0.28 ]
Total events: 2 (Immunotherapy), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.94 (P = 0.000081)
2 1 to 3 years of treatment
Oude Elberink 2009 0/3 0/2 Not estimable
Subtotal (95% CI) 3 2 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Over 3 years of treatment
Valentine 1990 1/24 7/27 28.1 % 0.16 [ 0.02, 1.21 ]
Subtotal (95% CI) 24 27 28.1 % 0.16 [ 0.02, 1.21 ]
Total events: 1 (Immunotherapy), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Total (95% CI) 113 92 100.0 % 0.10 [ 0.03, 0.28 ]
Total events: 3 (Immunotherapy), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.28 (P = 0.000018)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 6.4. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 4
Systemic reaction to field or challenge sting by insect species.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 4 Systemic reaction to field or challenge sting by insect species









Severino 2008 0/14 1/12 31.6 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 14 12 31.6 % 0.29 [ 0.01, 6.50 ]
Total events: 0 (Immunotherapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 Wasp
Oude Elberink 2009 0/3 0/2 Not estimable
Subtotal (95% CI) 3 2 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Ant
Brown 2003 1/35 21/29 68.4 % 0.04 [ 0.01, 0.28 ]
Subtotal (95% CI) 35 29 68.4 % 0.04 [ 0.01, 0.28 ]
Total events: 1 (Immunotherapy), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
Total (95% CI) 52 43 100.0 % 0.07 [ 0.01, 0.48 ]
Total events: 1 (Immunotherapy), 22 (Control)
Heterogeneity: Tau2 = 0.34; Chi2 = 1.19, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =12%
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Analysis 6.5. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 5
Systemic reaction to field or challenge sting by updosing schedule.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 5 Systemic reaction to field or challenge sting by updosing schedule








1 Rush or ultrarush
Oude Elberink 2009 0/3 0/2 Not estimable
Subtotal (95% CI) 3 2 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Weekly or 2-weekly
Brown 2003 1/35 21/29 34.4 % 0.04 [ 0.01, 0.28 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/18 7/12 33.7 % 0.10 [ 0.01, 0.68 ]
Valentine 1990 1/24 7/27 31.8 % 0.16 [ 0.02, 1.21 ]
Subtotal (95% CI) 96 78 100.0 % 0.08 [ 0.03, 0.26 ]
Total events: 3 (Immunotherapy), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000019)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 6
Systemic adverse reaction to treatment by route of immunotherapy.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 6 Systemic adverse reaction to treatment by route of immunotherapy









Brown 2003 13/35 1/32 71.6 % 11.89 [ 1.65, 85.80 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/19 0/20 28.4 % 3.15 [ 0.14, 72.88 ]
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Subtotal (95% CI) 135 120 100.0 % 8.16 [ 1.53, 43.46 ]
Total events: 14 (Immunotherapy), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Sublingual immunotherapy
Severino 2008 0/15 0/15 Not estimable
Subtotal (95% CI) 15 15 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 7
Systemic adverse reaction to treatment by age.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 7 Systemic adverse reaction to treatment by age








1 Under 18 years
2 Aged 18 years or over
Brown 2003 13/35 1/32 11.89 [ 1.65, 85.80 ]
Golden 2009 0/19 0/10 Not estimable
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Severino 2008 0/15 0/15 Not estimable
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Analysis 6.8. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 8
Systemic adverse reaction to treatment by duration of immunotherapy.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 8 Systemic adverse reaction to treatment by duration of immunotherapy








1 Under 1 year of treatment
Brown 2003 13/35 1/32 71.6 % 11.89 [ 1.65, 85.80 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/19 0/20 28.4 % 3.15 [ 0.14, 72.88 ]
Severino 2008 0/15 0/15 Not estimable
Subtotal (95% CI) 88 77 100.0 % 8.16 [ 1.53, 43.46 ]
Total events: 14 (Immunotherapy), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
2 1 to 3 years of treatment
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Subtotal (95% CI) 62 58 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Over 3 years of treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 9
Systemic adverse reaction to treatment by insect species.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 9 Systemic adverse reaction to treatment by insect species









Severino 2008 0/15 0/15 Not estimable
Subtotal (95% CI) 15 15 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Wasp
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Subtotal (95% CI) 62 58 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Ant
Brown 2003 13/35 1/32 100.0 % 11.89 [ 1.65, 85.80 ]
Subtotal (95% CI) 35 32 100.0 % 11.89 [ 1.65, 85.80 ]
Total events: 13 (Immunotherapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 Planned subgroup analyses - Immunotherapy versus control, Outcome 10
Systemic adverse reaction to treatment by updosing schedule.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 6 Planned subgroup analyses - Immunotherapy versus control
Outcome: 10 Systemic adverse reaction to treatment by updosing schedule








1 Rush or ultrarush
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Subtotal (95% CI) 62 58 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Weekly or 2-weekly
Brown 2003 13/35 1/32 71.6 % 11.89 [ 1.65, 85.80 ]
Golden 2009 0/19 0/10 Not estimable
Hunt 1978 1/19 0/20 28.4 % 3.15 [ 0.14, 72.88 ]
Subtotal (95% CI) 73 62 100.0 % 8.16 [ 1.53, 43.46 ]
Total events: 14 (Immunotherapy), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Unplanned subgroup analyses - Immunotherapy versus control, Outcome 1
Systemic reaction to field or challenge sting by history of prior systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 7 Unplanned subgroup analyses - Immunotherapy versus control
Outcome: 1 Systemic reaction to field or challenge sting by history of prior systemic reaction








1 No prior systemic reaction to insect sting
Golden 2009 0/19 0/10 Not estimable
Severino 2008 0/14 1/12 11.8 % 0.29 [ 0.01, 6.50 ]
Subtotal (95% CI) 33 22 11.8 % 0.29 [ 0.01, 6.50 ]
Total events: 0 (Immunotherapy), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 Prior systemic reaction to insect sting
Brown 2003 1/35 21/29 30.3 % 0.04 [ 0.01, 0.28 ]
Hunt 1978 1/18 7/12 29.8 % 0.10 [ 0.01, 0.68 ]
Oude Elberink 2009 0/3 0/2 Not estimable
Valentine 1990 1/24 7/27 28.1 % 0.16 [ 0.02, 1.21 ]
Subtotal (95% CI) 80 70 88.2 % 0.08 [ 0.03, 0.26 ]
Total events: 3 (Immunotherapy), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 4.27 (P = 0.000019)
Total (95% CI) 113 92 100.0 % 0.10 [ 0.03, 0.28 ]
Total events: 3 (Immunotherapy), 36 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.28 (P = 0.000018)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 7.2. Comparison 7 Unplanned subgroup analyses - Immunotherapy versus control, Outcome 2
Systemic adverse reaction to treatment by history of prior systemic reaction.
Review: Venom immunotherapy for preventing allergic reactions to insect stings
Comparison: 7 Unplanned subgroup analyses - Immunotherapy versus control
Outcome: 2 Systemic adverse reaction to treatment by history of prior systemic reaction








1 No prior systemic reaction to insect sting
Golden 2009 0/19 0/10 Not estimable
Severino 2008 0/15 0/15 Not estimable
Subtotal (95% CI) 34 25 Not estimable
Total events: 0 (Immunotherapy), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Prior systemic reaction to insect sting
Brown 2003 13/35 1/32 71.6 % 11.89 [ 1.65, 85.80 ]
Hunt 1978 1/19 0/20 28.4 % 3.15 [ 0.14, 72.88 ]
Oude Elberink 2006 0/47 0/44 Not estimable
Oude Elberink 2009 0/15 0/14 Not estimable
Subtotal (95% CI) 116 110 100.0 % 8.16 [ 1.53, 43.46 ]
Total events: 14 (Immunotherapy), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Immunotherapy Favours Control
A D D I T I O N A L T A B L E S
Table 1. Adverse effects - observational studies (Pharmalgen)
Study Systemic reaction to treatment Large local reaction to treatment
Carballada 2003 Bee = 37/3269 (1.1%) doses; 22/208 (10.6%) par-
ticipants
Wasp = 0/33 (0%) participants
31/3269 (0.9%) doses; 26/208 (12.5%) participants
6/428 (1.4%) doses; 5/33 (15.2%) participants
Carballada 2009 Bee = 2/21 (9.5%) participants 3/21 (14.3%) participants
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Table 1. Adverse effects - observational studies (Pharmalgen) (Continued)
Carballada 2010 Bee = 50/438 (11.4%) participants
(72 % grade 1 reactions; 4% grade 2; 10% grade 3;
1% grade 4)
Wasp = 0/124 (0%) participants
-
Fricker 1997 Bee or wasp = 2/10 (20%) participants -
Haeberli 2003 Bee = 18/104 (17.3%) participants
Wasp = 4/57 (7.0%) participants
-
Kalogeromitros 2010 Bee = 7/29 (24.1%) participants
Wasp = 2/18 (11.1%) participants
33/1520 (2.2%) doses overall
-




Muller 1992 Wasp = 2/57 (4%) participants
(objective systemic reactions)
-
Ramirez 1981 Bee or wasp = 0/22 (0%) participants 36/859 (4.2%) doses
Sanchez-Machin 2010 Bee = 2/54 (3.7%) participants; 4/324 (1.2%) doses 58/324 (17.9%) doses
Schiavino 2004 Bee or wasp = 4/56 (7.1%) participants 6/56 (10.7%) participants (’severe’ local reactions)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy (Cochrane Library)
#1 MeSH descriptor Hymenoptera explode all trees
#2 MeSH descriptor Arthropod Venoms explode all trees
#3 (bee or wasp or ant or hymenoptera or hornet or venom)
#4 MeSH descriptor Bees explode all trees
#5 MeSH descriptor Ants explode all trees
#6 MeSH descriptor Wasps explode all trees
#7 MeSH descriptor Ant Venoms explode all trees
#8 MeSH descriptor Bee Venoms explode all trees
#9 MeSH descriptor Wasp Venoms explode all trees
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Insect Bites and Stings explode all trees
#12 MeSH descriptor Hypersensitivity explode all trees
#13 MeSH descriptor Anaphylaxis explode all trees
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#14 MeSH descriptor Shock explode all trees
#15 MeSH descriptor Death explode all trees
#16 MeSH descriptor Edema explode all trees
#17 MeSH descriptor Urticaria explode all trees










#28 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27)
#29 MeSH descriptor Immunotherapy explode all trees
#30 MeSH descriptor Epinephrine explode all trees
#31 MeSH descriptor Desensitization, Immunologic explode all trees








#40 (#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39)
#41 (#10 AND #28 AND #40)
Appendix 2. MEDLINE search strategy (OVID)
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. bees.mp. or exp BEES/
12. bee venom.mp. or exp Bee Venoms/
13. (honey adj bee).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
14. honeybee.mp.
15. hymenoptera.mp. or exp HYMENOPTERA/
16. apis mellifera.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. wasps.mp. or exp WASPS/
18. wasp venom.mp. or exp Wasp Venoms/
19. vespid.mp.
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25. ants.mp. or exp ANTS/
26. ant venom.mp. or exp Ant Venoms/
27. exp Arthropod Venoms/
28. solenopsis invicta.mp.
29. myrmecia pilosula.mp.
30. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. exp “Insect Bites and Stings”/
32. (venom adj allergy).mp.
33. exp HYPERSENSITIVITY, DELAYED/ or exp HYPERSENSITIVITY/ or hypersensitivity.mp. or exp HYPERSENSITIVITY,
IMMEDIATE/
34. exp Anaphylaxis/ or anaphyla$.mp.
35. (allergic or allergy).mp.
36. swelling.mp.
37. exp EDEMA/ or edema.mp.
38. systemic reaction.mp.
39. shock.mp. or exp SHOCK, TRAUMATIC/ or exp SHOCK/
40. hives.mp. or exp Urticaria/
41. laryngeal obstruction.mp.
42. exp Death/ or exp Death, Sudden/ or death.mp.
43. exp Angioedema/ or exp Airway Obstruction/
44. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. exp IMMUNOTHERAPY, ACTIVE/ or immunotherapy.mp. or exp IMMUNOTHERAPY/
46. adrenaline.mp. or exp Epinephrine/
47. epipen.mp.
48. (venom adj immunotherapy).mp.




53. desensiti$.mp. or Desensitization, Immunologic/
54. dose response relationship immunologic.mp. or exp Dose-Response Relationship, Immunologic/
55. hyposensitization.mp.
56. 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55
57. 30 and 44 and 56
58. 10 and 57
Appendix 3. EMBASE search strategy (OVID)
1. bee.mp. or exp BEE/
2. bee venom.mp. or exp bee venom/
3. honey bee.mp. or exp honeybee/
4. exp HYMENOPTERA VENOM/ or exp HYMENOPTERA/ or hymenoptera.mp.
5. apis mellifera.mp.
6. exp WASP/ or wasp.mp.
7. wasp venom.mp. or exp wasp venom/
8. vespid.mp.
9. vespula.mp.
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14. exp ANT/ or ant.mp.
15. ant venom.mp. or exp ant venom/
16. arthropod venom.mp. or exp arthropod venom/
17. solenopsis invicta.mp.
18. myrmecia pilosula.mp.
19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. insect sting.mp. or exp insect sting/
21. insect bite.mp. or exp insect bite/
22. insect allergy.mp. or exp insect allergy/
23. venom allergy.mp.
24. hypersensitivity.mp. or exp IMMEDIATE TYPE HYPERSENSITIVITY/ or exp DELAYED HYPERSENSITIVITY/ or exp




28. exp INSECT ALLERGY/ or exp ALLERGY/ or allergy.mp.
29. swelling.mp. or exp SWELLING/
30. edema.mp. or exp EDEMA/
31. systemic reaction.mp. or exp allergic reaction/
32. exp SHOCK/ or exp TRAUMATIC SHOCK/ or shock.mp.
33. hives.mp. or exp urticaria/
34. laryngeal obstruction.mp. or exp larynx stenosis/
35. exp DEATH/ or exp SUDDEN DEATH/ or death.mp.
36. angioedema.mp.
37. airway obstruction.mp. or exp airway obstruction/
38. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
39. immunotherapy.mp. or exp IMMUNOTHERAPY/
40. adrenaline.mp. or exp adrenalin/
41. epipen.mp.
42. venom immunotherapy.mp.
43. specific immunotherapy for hymenoptera venom.mp.
44. exp immunomodulation/ or immunomodulatory.mp.
45. immune therapy.mp. or exp immunotherapy/
46. immunologic response.mp. or exp immune response/
47. exp DESENSITIZATION/ or desensitization.mp.
48. exp dose response/ or immunologic dose response relationship.mp.
49. hyposensitization.mp.
50. 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49
51. random$.mp.
52. factorial$.mp.
53. (crossover$ or cross-over$).mp.
54. placebo$.mp. or PLACEBO/
55. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer]
56. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer]
57. (assign$ or allocat$).mp.
58. volunteer$.mp. or VOLUNTEER/
59. Crossover Procedure/
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60. Double Blind Procedure/
61. Randomized Controlled Trial/
62. Single Blind Procedure/
63. 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64. 19 and 38 and 50
65. 63 and 64




4. 1 or 2 or 3
5. wasp.mp. or exp Wasps/
6. ant.mp. or exp Ants/
7. bee.mp. or exp Bees/
8. hornet.mp.
9. venom.mp.





15. exp Anaphylactic Shock/ or anaphylaxis.mp.
16. exp Allergic Disorders/
17. swelling.mp.
18. edema.mp.




23. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. exp immunotherapy/
25. immune therapy.mp.
26. adrenaline.mp. or exp Epinephrine/
27. desensiti$.tw.
28. hyposensitization.tw.
29. 24 or 25 or 26 or 27 or 28
30. 10 and 23 and 29
31. 4 and 30
Appendix 5. AMED search strategy (OVID)
1. exp Apis mellifica/ or bee.mp.
2. wasp.mp.
3. exp insects/ or ant.mp.
4. hornet.mp. or exp Venoms/
5. 1 or 2 or 3 or 4
6. bite.mp.
7. sting.mp. or exp “Bites and stings”/
8. allerg$.tw.
9. exp Shock/ or exp Anaphylaxis/ or shock.mp.
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10. exp Death/ or death.mp.
11. 6 or 7 or 8 or 9 or 10
12. 5 and 11
13. immunotherapy.mp. or exp Immunotherapy/
14. 5 and 13
Appendix 6. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Words] and alergia or
alergeno [Words] and picadura or insecto [Words]
WH A T ’ S N E W
Last assessed as up-to-date: 21 February 2012.
Date Event Description
18 December 2014 Review declared as stable There were no ongoing studies or studies awaiting classification listed in the last
published review, but a search of MEDLINE and Embase in October 2013 found
2 more studies. However, the review team confirmed that neither of these trials
would meet the review’s inclusion criteria, so the update was postponed. Another
search in December 2014 did not identify any further trials, so we have marked
this review as stable. Our Trials Search Co-ordinator will run a new search towards
the end of 2015 to re-assess whether an update is needed
C O N T R I B U T I O N S O F A U T H O R S
ME was the contact person with the editorial base at the protocol stage, and RB, at the review stage. RB co-ordinated contributions
from the co-authors and wrote the final draft of the review.
ME and RB screened papers against eligibility criteria.
ME and RB obtained data on ongoing and unpublished studies.
ME and RB appraised the quality of papers.
ME and RB extracted data for the review and sought additional information about papers.
ME and RB entered data into RevMan.
JH and MC undertook the adverse events search and summarised the adverse events data.
RB analysed and interpreted data, with advice from MB.
ME and RB drafted the clinical sections of the background, with contributions from all authors.
RB responded to the referees’ comments. All authors reviewed and commented on the review.
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MD was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to
consumers.
RB is the guarantor of the update.
D E C L A R A T I O N S O F I N T E R E S T
Robert Boyle has received research funding from Lincoln Medical Ltd and support for conference attendance fromMeda Pharmaceuti-
cals, both of which market adrenaline autoinjector devices, and his department has received research support from Allergy Therapeutics
who market allergen immunotherapy products, including venom immunotherapy.
Hanneke Oude Elberink (J.N.G. Oude Elberink) undertook two of the trials included in this review. She has received research support
from ALK-Abello who market allergen immunotherapy, and HAL Allergy; she has received honorarium from MSD, Allergopharma,
ALK-Abello, and AstraZeneca; and she has received fees for consulting from ALK-Abello and HAL Allergy.
Mariam Elremeli, Max Bulsara, Juliet Hockenhull, Gemma Cherry, and Michael Daniels have no interests to declare.
A clinical referee on the review, Dr Cristoforo Incorvaia, has received fees as a scientific consultant from the producer of allergen extracts,
Stallergenes.
S O U R C E S O F S U P P O R T
Internal sources
• Imperial College London, UK.
• National Institute for Health Research Biomedical Research Centre, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Hanneke Oude Elberink joined as a co-author. We changed the order of the secondary outcomes. In the Data Collection and Analysis
section (Measures of treatment effect), we elaborated on how we analysed the risk of systemic reaction. We added a post-hoc subgroup
analysis according to the severity of the previous reaction to insect sting. We included quasi-randomised trials, which had not been
specifically considered for inclusion or exclusion at the protocol stage.
N O T E S
There were no ongoing studies or studies awaiting classification listed in the last published review, but a search of MEDLINE and
Embase in October 2013 found 2 more studies. However, the review team confirmed that neither of these trials would meet the review’s
inclusion criteria, so the update was postponed. Another search in December 2014 did not identify any further trials, so we have marked
this review as stable. Our Trials Search Co-ordinator will run a new search towards the end of 2015 to re-assess whether an update is
needed.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Allergens [∗administration & dosage; adverse effects; immunology]; Ants [∗immunology]; Bee Venoms [∗administration & dosage;
adverse effects; immunology]; Desensitization, Immunologic [adverse effects; ∗methods]; Insect Bites and Stings [immunology;
∗prevention & control]; Randomized Controlled Trials as Topic; Wasp Venoms [∗administration & dosage; adverse effects; immunol-
ogy]
MeSH check words
Adult; Animals; Child; Humans
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